JACKSON CENTER, PA / ACCESSWIRE / January 14, 2021 / Halberd Corp. (OTC PINK:HALB) announced the filing of a provisional patent application on a proprietary combination of nutritional supplements (melatonin, zinc and Vitamin D) combined with low dose Naltrexone designed to reduce the severity of Covid-19 symptoms. This proprietary combination of supplements is based on numerous peer-reviewed publications (1, 2, 3, 4, 5, 6, 7) from major medical organizations indicating that each of the ingredients contributes to reduced Covid-19 symptomology. Halberd intends to make the proprietary nutritional supplement formula portion available as an over-the-counter product as soon as possible. The prescription-based medication with the addition of low dose Naltrexone would be available after FDA approval is obtained.
Halberd will have exclusive worldwide rights to the provisional patent application, “Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus)”.
William A. Hartman, Chairman, President & CEO, stated, “Our scientists have formulated a specific combination of nutritional supplements which they believe, after reviewing numerous peer-reviewed medical articles and independent research, should provide a boost to the immune system to reduce the severity of Covid-19, when taken prior to contracting the disease or early in its onset. Each participating medical expert agrees that there would be no downside in the use of any of these ingredients.
We are excited about the prospects of securing immediate volume manufacturing and mass distribution sources for our products. A significant portion of the revenue from these initial products will be reinvested in expanding and accelerating our research programs and developing market readiness of follow-on products.”
To be added to Halberd’s email subscriber list, click here and submit the form.
About Halberd Corporation.
Halberd Corporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here.
The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus,” “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” “Nasal Spray to Prevent the Transmission of Covid-19,” and “Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus,” “Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus).” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com: